NOVO NORDISK a/S

New real‑world data show Wegovy® drives 10.4% weight loss and 32% ALT drop in MASH patients, supporting a future FDA/EMA approval.

Explore how Novo Nordisk’s insider trades, partnership wind‑down, and Q3 earnings impact its obesity‑focused outlook and market stance.

Explore Novo Nordisk’s earnings, weight‑loss portfolio growth, competitive risks, and future outlook in this concise market analysis.

How Novo Nordisk’s new weight‑loss drug could lift Q3 revenue and EPS, amid share‑repurchase and supply‑chain strategy insights.

How Novo Nordisk’s rising GLP‑1 share mix fuels a 2% stock jump – but patent cliffs, competition and regulation could threaten future gains.

Explore Eli Lilly’s 2026 outlook—higher sales and steady EPS—driven by its powerful injectable weight‑loss and diabetes therapies, and insights on market dynamics.

Discover why Novo Nordisk remains a top choice for investors in obesity & diabetes, with strong margins, a robust pipeline, and strategic pricing that beats rivals.

New leadership at Evotec SE ties Novo Nordisk’s research strengths to rising biologics demand, while a modest C25 index gain reflects investor confidence in its drug pipeline and market strategy.